v3 Chapter 762： Greedy hunter

In the evening, Xia Yu convened all members of the acquisition team to summarize today's results and agree on tomorrow's plan based on the situation.

As soon as you come up, you first report the status of each group.

Needless to say, Xia Yu won all of them that day.

Peter Lynch’s second group is in charge of York Capital.

He reported to Xia Yuhui: "Chairman, today we negotiated with the CEO of York Capital for a day. They have agreed to sell the equity. The difficulty now is that the price cannot be agreed."

"York Capital offered 55 million U.S. dollars. Due to time constraints, the negotiations were terminated."

Xia Yu nodded slightly and looked at Brandon Gus, the third group leader. The latter immediately said: "Chairman, Conston Capital is very confident in Genentech and has refused to sell its shares until the afternoon. We only persuaded them to agree to sell the equity, but they offered a very high price, 8.6 percent of the equity asking for 21.5 million US dollars!"

According to this price, it can be seen that their valuation of Genentech is US$250 million, which is US$50 million higher than the valuation of Coller Perkins!

But Xia Yu also expressed understanding, because at the beginning, he predicted that Conston Capital's attitude towards selling shares would be the most negative.

After all, they joined in the third round of financing after defeating a lot of opponents. They are destined to have the most confidence in Genentech.

And the latest entry means that their appetite will be the greatest. They also have the capital strength to take this risk, and they have the strength to wait for GeneTek to go public.

Unlike Coller Perkins, which has weak capital and has never seen the big world, Xia Yu’s higher bid made them obediently surrender.

After signaling Brandon Gus to sit down, Xia Yu said with a smile: "In fact, the situation is pretty good. Although it was not successful on the day, both of you successfully convinced them to sell the equity. The difference is only the price."

"York Capital’s valuation of Genentech is US$220 million, while Conston Capital’s valuation is US$250 million. I am responsible for the acquisition of Coller Perkins. The valuation is only 200 million U.S. dollars, and the gap here is indeed a bit big."

"But it doesn't matter. Conston Capital has the lowest shareholding ratio. Even if the valuation is high, it will cost one or two million dollars more. Promise them!"

"You can tell them the price of Coller Perkins today to keep the price down!"

"I have just one request. Tomorrow, the acquisition must be ended. This is the company's first action. I don't want accidents! I hope you can perform well!"

The hearts of the crowd shivered, and they agreed in unison.

Then, continue to discuss the detailed tackling strategy, and strive to let York Capital and Conston Capital follow the pace of Polaris Capital tomorrow!

...

Early the next morning, Peter Lynch and Brandon Gus set out again.

And Xia Yu brought his subordinates and others to Genentech.

He did not forget that Professor Herb Boyle wanted to see him.

And the equity in Professor Herb Boyle's hands is also something he covets.

Xia Yu waited in the reception room for less than five minutes, and saw an elderly man in his fifties wearing glasses walking in.

Xia Yu saw the photo and immediately recognized it. This person was Professor Herb Boyle.

He immediately got up and greeted with a slight respect: "Professor Herb Boyle, hello, I am the chairman of Polaris Capital, my name is Xia Yu, you can call me Xia."

Professor Herb Boyle was not arrogant. He smiled, shook hands with Xia Yu, and called Xia Yu's name awkwardly, and said, "Hello, Mr. Xia! Please sit down!"

"Thank you, please sit down too!"

After being seated one after another, Professor Herb Boyle asked bluntly: "Mr. Xia, Robert Swanson told me yesterday that the shares in their company have been sold to you, and you have agreed to my terms. Now we are facing each other. I want to know what is your purpose in acquiring Genentech? What is your attitude?"

It's worthy of being a scientific researcher, speaking straight and straight, but this kind of personality is just right, there are not so many intestines, as long as you touch the right door, you will actually get along well.

Xia Yu smiled and said: "Professor Herb Boyle, the reason why we acquired Genentech is because we are very optimistic about you. We believe that your research can benefit the world, so we are willing to help you push your research results. To the world, by the way, get some compensation in this process."

What Xia Yu said was very artistic. Even Professor Herb Boyle didn't like people to flatter, but the corners of his mouth were raised slightly, his complexion softened a lot, and he got a lot closer to Xia Yu.

Professor Herb Boyle forced a smile and said: "Mr. Xia, if you really have this attitude, then I welcome you!"

Xia Yu nodded immediately, speaking very openly: "Of course, we will fully support your research."

"By the way, Professor Herb Boyle, we are very optimistic about you, so in addition to acquiring the equity of Coller Perkins, we are also acquiring equity of York Capital and Conston Capital."

In a few simple words, Xia Yu already knows the nature of Professor Herb Boyle, so in order to avoid misunderstandings, he clarified the matter.

Professor Herb Boyle really didn’t know the news. He frowned, staring at Xia Yu, and said: “You bought the shares of the two companies, then Genentech’s listing process will be terminated. But the production of my research and patents requires a lot of money!"

Xia Yu looked at him calmly, and immediately said: "This is not a problem, Professor Herb Boyle, no matter how much money you need, our Polaris Capital can inject capital! As long as you need it!"

After that, in order to dispel Professor Herb Boyle’s doubts, Xia Yu also shifted his mind and said: “Professor Herb Boyle, in fact, you should know that there are advantages to listing companies, but there are also disadvantages. Tektronix has encountered difficulties, the stock market will transmit tremendous pressure to you, your plans will be subject to stricter approvals, and the spotlight of the media will always shine on you, making you unable to conduct scientific research at ease!"

Xia Yu’s words are very reasonable. Professor Herb Boyle has also learned about the advantages and disadvantages of the stock market in his spare time, and he is naturally aware of past cases.

"As far as I know, Genentech went public because the next scientific research and expansion will require a large amount of funds. Now we can bear the money. I hope you can avoid being disturbed by the noisy outside world. We will do our best for you. Create a better scientific research environment."

Professor Herb Boyle was able to win the Nobel Prize, and he was naturally a person who was fascinated by experiments. If the funds required for the next expansion were not too large, the three limelight companies might not be able to afford it, and he would not be encouraged to agree. The company applies for listing.

Currently, only two of his scientific research results have been released, and both of them are still under review. They have not yet been put into production, and risks still exist.

Since Xia Yu's North Star Capital is willing to take over, he also hopes that he can continue to study quietly.

As for the issue that his equity will be diluted after Polaris Capital injects capital, he does not care, he is not keen on money, and even he has the idea of ​​setting up a scientific research fund after his death, which is for the latecomers in the DNA field. Research provides support.

There is a great chance of luck for his success, but not every time the goddess of fortune comes, so he does not hope that latecomers will also struggle to find the truth because of the difficult scientific research conditions.

"Mr. Xia, you are welcome to join!"

Professor Herb Boyle said with a smile.

"Professor Herb Boyle, thank you, I believe we will get along very happily in the future!" Xia Yu said with a smile, shaking hands with him again.

Professor Herb Boyle smiled and nodded: "I hope so!"

"Now the company's funds are not enough. After you finish the acquisition, I hope you can inject funds as soon as possible!"

"No problem, if the acquisition can be ended today, then we can inject capital at any time, everything is based on your wishes!"

...

Xia Yu had a very pleasant chat with Professor Herb Boyle, but the latter was thinking about his experiment, and after resolving the doubts in his heart, he said goodbye and hurried back to the laboratory.

In the afternoon, the acquisitions of both groups were completed.

Among them, Peter Lynch took out the case of Coller Perkins, and York Capital’s psychological defenses collapsed at once, and finally took up 2% of his holdings at a price of 51 million US dollars. Fifteenth equity transfer.

As for Brandon Gus, he did his best to reduce Genentech’s valuation to US$220 million.

Therefore, the transfer price of the 8.6% equity held by Conston Capital is $18.92 million.

So far, Polaris Capital has spent a total of US$119.92 million to acquire 58.6% of the shares and become the largest shareholder of Genentech.

Xia Yu is very satisfied with this price.

Because he knows that the capital market is very enthusiastic about Genentech. According to the historical trajectory Genentech's stock price rose from 35 U.S. dollars to the highest of 88 U.S. dollars even at the closing price. , Also exceeded 70 US dollars, and the market value directly reached 300 million US dollars.

Now it is very worthwhile to cut the Husband half a year ahead of schedule, and control Genentech’s valuation to just over 200 million US dollars.

Of course, if you consider Genentech's future market value of 100 billion yuan, it will be more worthwhile!

After completing the acquisition, Xia Yu immediately approached Professor Herb Boyle to discuss the capital injection.

In order to leave a good impression, Xia Yu was not too harsh, and valued the current Genentech company at US$210 million.

And in order to obtain as much equity as possible, Xia Yu, from the perspective of Professor Herb Boyle, constantly encourages him to develop by leaps and bounds, buy newer and better experimental instruments, and build a top laboratory. And directly build a large factory.

In short, how to spend money is to take advantage of this rare opportunity to obtain as much equity as possible.

If you don't seize the opportunity to come here this time, you won't know the year of the monkey next time, and the cost will be extremely scary by then!

Professor Herb Boyle was irritated by Xia Yu and felt very good for Xia Yu.

In the end a huge expansion plan was made, and the negotiation decided to inject 50 million US dollars into the company at one time!

After the capital injection, Xia Yu's shareholding ratio increased by 19.23%.

The total shareholding ratio increased to 77.83%.

Professor Herb Boyle’s shareholding ratio dropped from 41.4% to 22.17%!

At this point, Xia Yu can officially announce!

Genentech, the hunting success!

https://

Please remember the domain name of this book's first publication:. Apex novel mobile version reading URL: